With a 23% holdings overlap as of April 2026, WTAI and WQTM offer complementary exposure to the shared pursuit of greater ...
AstraZeneca announces positive results from MULBERRY phase III trial of efzimfotase alfa, an investigational enzyme replacement therapy: Cambridge, UK Tuesday, June 30, 2026, 11:0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results